(Q34497797)

2 August 2017

title

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (English)

1 reference

2 August 2017

0 references

1 reference

5

Angela Dispenzieri

1 reference

2 August 2017

10

Robert A Kyle

1 reference

2 August 2017

4

Martha Q Lacy

1 reference

2 August 2017

8

Stephen J Russell

1 reference

2 August 2017

13

S Vincent Rajkumar

1 reference

2 August 2017

3

Morie A Gertz

1 reference

2 August 2017

2

Suzanne Hayman

1 reference

2 August 2017

7

Steven R Zeldenrust

1 reference

2 August 2017

9

John A Lust

1 reference

2 August 2017

6

Shaji Kumar

1 reference

2 August 2017

12

Thomas E Witzig

1 reference

2 August 2017

11

Philip R Greipp

1 reference

Kristen E Detweiler Short

2 August 2017

series ordinal

1

object named as

Kristen Detweiler-Short

1 reference

2 August 2017

publication date

1 October 2010

1 reference

American Journal of Hematology

2 August 2017

published in

1 reference

2 August 2017

volume

85

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

737-740

1 reference

Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Improved survival in multiple myeloma and the impact of novel therapies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

International uniform response criteria for multiple myeloma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Thalidomide for previously untreated indolent or smoldering multiple myeloma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Antitumor activity of thalidomide in refractory multiple myeloma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Thalidomide is an inhibitor of angiogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Thalidomide as initial therapy for early-stage myeloma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3022372

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20730790

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinically relevant end points and new drug approvals for myeloma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20730790

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/AJH.21821

1 reference

2 August 2017

1 reference

2 August 2017

1 reference